Methods for generating functional pancreatic islets from pluripotent stem cells

JP2024543217A5Inactive Publication Date: 2024-12-09HANGZHOU REPROGENIX BIOSCIENCE INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024532849
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2021-11-30
Publication Date
2024-12-09
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current methods for differentiating human pluripotent stem cells into functional pancreatic islets face challenges in efficiency and reproducibility, and their feasibility in large animal models relevant to humans, particularly non-human primates, is uncertain, limiting their clinical application.

Method used

A differentiation protocol is established that includes culturing hPSCs through sequential media stages, supplemented with ISX9 and Wnt-C59, to generate functional hPSC-islets, which are then transplanted into diabetic animal models, demonstrating efficient and reproducible production of uniform islet-sized aggregates.

Benefits of technology

The protocol produces functional hPSC-islets that survive and restore endogenous insulin secretion, improving glycemic control and reducing hyperglycemia in diabetic animal models, including non-human primates, with high survival rates and sustained C-peptide secretion.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present disclosure provides a method for generating functional hPSC-islets in vitro, the method comprising generating pancreatic endocrine precursor cells from pancreatic progenitor cells by using a medium supplemented with ISX9 or a combination of ISX9 and Wnt-C59. Also provided are the medium used in the method, the population of cells comprising functional hPSC-islets generated by the method, and uses thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure relates to biotechnology, and more particularly to a method, a combination of agents and a kit for generating functional hPSC-islets (human pluripotent stem cell derived pancreatic islets) in vitro. The present disclosure also relates to a method for producing functional hPSC-islets (human pluripotent stem cell derived pancreatic islets) in vitro, and a method for producing ... vivo. + Cells, Glucagon + Cells and Somatostatin + The invention also relates to a population of functional hPSC-islets comprising the cells, a pharmaceutical composition comprising the population of functional hPSC-islets, and a method of treating a mammal having or at risk of having diabetes by administering the functional hPSC-islets. [Background technology]

[0002] Cell replacement therapy holds promise in the treatment of diseases such as type 1 diabetes mellitus (T1DM), which is primarily caused by the loss of pancreatic islet β cells. Human islet transplantation has been shown to reverse T1DM by effectively restoring endogenous insulin secretion in patients. However, the widespread application of islet transplantation is significantly hindered by the lack of an easily accessible source of human islets.

[0003] China Patent Publication No. 102899288 discloses a method for differentiating human islet-derived pancreatic stem cells into insulin-producing cells. The method begins with harvesting human islets and growing pancreatic stem cells therefrom. The starting material is donor-derived tissue that is not easily available, limiting the use of the method.

[0004] Several research groups have reported in vitro methods to obtain insulin-producing cells from human pluripotent stem cells (hPSCs), which allowed to obtain a nearly homogenous population of pancreatic fate-committed PDX1+ progenitor cells (A. Rezania. Et al., Nat Biotechnol. 2014 Nov;32(11):1121-33; FW Pagliuca, et al., Cell 159,428-439, Oct.9,2014). However, the subsequent commitment of these progenitor cells to pancreatic β cells with high efficiency remained a challenge. Moreover, the feasibility of this stem cell-based therapeutic strategy has not been systematically evaluated in large animal models with physiological similarity to humans, especially non-human primates. Uncertainties remain to translate the treatment with pluripotent stem cell-derived islets, which proved successful in the laboratory in mice, into clinical applications in humans, especially transplantation and therapy, which are difficult to explore using rodent animal models.

[0005] Thus, there remains a need for efficient and reproducible methods for the differentiation of functional pancreatic islets suitable for preclinical or clinical use from readily available sources. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] China Patent Application Publication No. 102899288 [Non-patent literature]

[0007] [Non-Patent Document 1] A.Rezania.Et al.,Nat Biotechnol.2014 Nov;32(11):1121-33 [Non-Patent Document 2] FWPagliuca,et al.,Cell 159,428-439,Oct.9,2014 Summary of the Invention [Problem to be solved by the invention]

[0008] The inventors established a differentiation protocol with high efficiency and good reproducibility, which is a prerequisite for meeting the cell quantity and quality thresholds of preclinical and translational research. The inventors focused on optimizing the differentiation protocol from the commitment of pancreatic progenitor cells to β-cell fate determination by regulating signaling pathways and reconstructing the spatial structure of pancreatic islets. Two factors were found to be critical: first, the formation of dense three-dimensional cell aggregates of posterior foregut-committed cells promoted the efficient generation of NKX6.1+C-peptide+ cells. Second, the addition of the small molecule ISX9 at stage 5 promoted the terminal differentiation of pancreatic endocrine progenitor cells, and a synergistic effect was achieved when ISX9 was added in combination with Wnt-C59. With this optimized protocol, the inventors were able to efficiently and reproducibly generate relatively uniform islet-sized aggregates that proved to be safe and efficient in a non-human primate model after transplantation, thus completing the present invention.

[0009] Thus, in general, the disclosure provides methods for generating functional hPSC-islets in vitro, agents and compositions for use in the methods, populations of functional hPSC-islets obtainable by the methods, pharmaceutical compositions comprising populations of functional hPSC-islets, methods of treating a mammal having or at risk of having diabetes, and kits for generating functional hPSC-islets. [Means for solving the problem]

[0010] In a first aspect, the present disclosure provides a method for generating functional hPSC-islets in vitro, comprising: (1) culturing the hPSCs in a sixth culture medium to obtain cells expressing markers characteristic of definitive endoderm; (2) culturing the cells obtained in step (1) in a fifth culture medium to obtain cells expressing markers characteristic of primitive intestinal cells; (3) culturing the cells obtained in step (2) in a fourth culture medium to obtain cells expressing markers characteristic of posterior foregut cells; (4) culturing the cells obtained in step (3) in a third culture medium to obtain cells expressing markers characteristic of pancreatic progenitor cells; (5) culturing the cells obtained in step (4) in a second culture medium to obtain cells expressing markers characteristic of pancreatic endocrine precursor cells; (6) culturing the cells obtained in step (5) in a first culture medium to obtain cells expressing markers characteristic of functional hPSC-islets; Methods are provided wherein the second culture medium is supplemented with ISX9 or Wnt-C59, preferably ISX9.

[0011] In a further embodiment, the second culture medium is supplemented with a combination of ISX9 and Wnt-C59 small molecules.

[0012] According to some embodiments of the present disclosure, the addition of ISX9, and preferably also Wnt-C59, synergistically promotes the differentiation of pancreatic progenitor cells into pancreatic endocrine precursor cells.

[0013] In another embodiment of the first aspect, the first culture medium is supplemented with one or more of an ALK5 inhibitor, an adenylyl cyclase activator, an Axl inhibitor, an IκB kinase inhibitor, a thyroid hormone, and ZnSO4.

[0014] According to some embodiments of the present disclosure, the inventors provide methods for generating functional pancreatic islets and demonstrate that transplantation of these islets into diabetic animal models, including rodent and non-human primate models, effectively restores endogenous insulin secretion and improves glycemic control.

[0015] In some embodiments, following transplantation under the kidney capsule of streptozotocin (STZ)-induced diabetic mice, hPSC-islets express C-peptide + β cells, GCG + Alpha cells and SST +They survived with prominent vascularization and preserved cellular complexity, as indicated by the presence of δ-cells. Fasting blood glucose levels of transplanted mice were restored to physiological levels, accompanied by an increase in body weight. Glucose tolerance tests showed glucose-responsive human C-peptide secretion as well as rapid glucose clearance. Fasting human C-peptide secretion steadily increased from 2 to 12 wpt and was then maintained at approximately 1 ng / mL for up to 36 weeks in nondiabetic mice. Notably, the 15-week survival rate of hPSC-islet transplanted diabetic mice was >85%, compared with <20% in the nontransplanted control group.

[0016] In some embodiments, after intraportal infusion of one dose of stem cell-derived islets in a non-human primate model, fasting blood glucose levels and mean pre-prandial blood glucose levels were significantly reduced in all recipients. Importantly, at 3 months post-transplant, mean HbA1c was reduced by more than 2% compared to peak values, while mean exogenous insulin requirements were reduced by 49% at 15 weeks post-transplant. Furthermore, C-peptide release in response to meals, glucose and arginine was observed in recipients. Notably, these improvements were also observed in recipient macaques with glycemic conditions similar to those of unstable diabetic patients, where islet replacement therapy confers significant clinical and potentially life-saving benefits. Taken together, our findings demonstrate the feasibility of pluripotent stem cell-derived islets for diabetes treatment in a pre-clinical setting, which represents an important step forward in the process of clinical translation of hPSC-islets.

[0017] In a second aspect, the present disclosure provides a population of functional hPSC-islets obtainable by the method of the first aspect. The population of functional hPSC-islets can be used to treat, for example, a mammal having or at risk of having type I diabetes, type II diabetes, pre-diabetes, or any combination thereof, by transplanting these islets in a subject in need of such treatment.

[0018] In a third aspect, the present disclosure provides a pharmaceutical composition comprising a population of functional hPSC-islets of the first aspect. The pharmaceutical composition can be used, for example, to treat a mammal having or at risk of having type I diabetes, type II diabetes, pre-diabetes, or any combination thereof, by transplanting these islets in a subject in need of such treatment.

[0019] In a fourth aspect, the disclosure provides a method of treating a mammal having or at risk of having type I diabetes, type II diabetes, prediabetes, or any combination thereof, comprising administering to the mammal a therapeutically effective amount of a population of functional hPSC-islets of the second aspect, or a pharmaceutical composition of the third aspect.

[0020] In a fifth aspect, the present disclosure provides a kit for generating functional hPSC-pancreatic islets, the kit comprising at least one of the first through seventh culture media.

[0021] In a specific embodiment of the fifth aspect, the second culture medium comprises ISX9 or Wnt-C59, preferably ISX9. In a further embodiment of the fifth aspect, the second culture medium comprises a combination of the small molecules ISX9 and Wnt-C59.

[0022] In a sixth aspect, the present disclosure relates to the use of ISX9 alone or in combination with Wnt-C59 in inducing differentiation of pancreatic progenitor cells into pancreatic endocrine precursor cells.

[0023] The above and other objects, features and advantages will become more apparent from the following description of the embodiments with reference to the drawings. [Brief description of the drawings]

[0024] [Figure 1]Figure 1 shows the establishment of an efficient protocol generating functional hPSC-derived islets in vitro that reverse diabetes in diabetic mice in vivo. a, Schematic of the differentiation protocol. b, Left: Representative brightfield image of stage 6 cell aggregates. Scale bar, 500 μm. Right: Representative flow cytometry analysis of expression of β-cell markers in stage 6 day 3 (S6D3) cell aggregates. c, Representative immunostaining of islet hormones in sectioned stage 6 aggregates. Scale bar, 50 μm. d, Percentage of islet hormone-positive cells in hPSC-islets detected by flow cytometry (n=6). (e-h) Transplanted hPSC-islets reversed diabetes in STZ-induced diabetic mice. e, Immunofluorescence staining of islet hormones and key markers of β-cells in hPSC-islet grafts at 16 wpt. Scale bar, 50 μm. f, Fasting blood glucose levels of hPSC-islet transplanted diabetic mice (n=22). g, Human C-peptide secretion in response to glucose loading in hPSC-islet transplanted mice at 16 wpt (n = 17). h, Sequential detection of fasting human C-peptide secretion in hPSC-islet transplanted non-diabetic mice; the first detection was performed at 2 wpt (n = 31). All data are presented as mean ± SEM. [Diagram 2] Figure 2 shows intraportal infusion of hPSC-islets leading to stabilization of blood glucose levels in immunosuppressed diabetic rhesus monkeys. Long-term follow-up of blood glucose measurements in diabetic monkey-1# (a, e, i), monkey-2# (b, f, j), monkey-3# (c, g, k) and monkey-4# (d, h, l) before and after infusion of hPSC-islets. (a–d) Daily fasting blood glucose levels of monkeys before and after infusion of hPSC-islets (infusion procedure was performed on day 0). (e–h) Average pre-prandial blood glucose levels of monkeys before and after hPSC-islets infusion. P values ​​reflect the statistical significance of the change of each group from pre-infusion (-1 month) levels. *P<0.05, **P<0.005, ***P<0.0005, ****P<0.00005. ns, not significant. Data presented as mean ± SEM. (il) Glycated hemoglobin (HbA1c) levels in monkeys before diabetes induction and before (0 wpt) and after hPSC-islet infusion. [Diagram 3] Figure 3 shows that hPSC-islet transplanted diabetic macaques showed a significant reduction in exogenous insulin requirement and an overall increase in body weight. Longitudinal follow-up of exogenous insulin requirement and body weight in diabetic monkey-1# (a,e), monkey-2# (b,f), monkey-3# (c,g) and monkey-4# (d,h) before and after infusion of hPSC-islets. (a-d) Average weekly exogenous insulin dose. Exogenous insulin requirement in the final week before infusion and in the final week before submission is shown above the bars. Data presented as mean ± SEM. (e-h) Follow-up of monkey body weight. [Figure 4] Figure 4 shows detection of C-peptide in hPSC-islet transplanted diabetic rhesus monkeys. Long-term tracking of C-peptide secretion in diabetic monkey-1# (a, e), monkey-2# (b, f), monkey-3# (c, g) and monkey-4# (d, h) before and after infusion of hPSC-islets. (a-d) Random C-peptide levels in transplanted monkeys before diabetes induction, before infusion (0 wpt) and after infusion. (e-h) Fasting and postprandial C-peptide secretion in transplanted monkeys. All data presented as mean ± SEM. [Diagram 5]Figure 5 shows the establishment of an efficient hPSC-islet generation protocol and characterization of hPSC-islets. a. Flow cytometry analysis comparing differentiation efficiency between flat plate and suspension cultures at various stages of the protocol with respect to pancreatic progenitor markers at the end of stage 4 and beta cell markers at the end of stage 6 (n=5). b. Flow cytometry of beta cell marker expression in stage 6 aggregates without and with the addition of small molecules ISX9 and Wnt-C59, individually or in combination, at stage 5, detected at S6D2 (n=4). c, Successive stage-by-stage tracking of pancreatic progenitor, endocrine precursor and beta cell markers by flow cytometry throughout the differentiation protocol (n=3). (d-h) In vitro characterization of stage 6 islet-like aggregates. d, Representative immunostaining of key beta cell transcription factors in sectioned stage 6 aggregates. Scale bar, 50 μm. e, C-peptide secretion of stage 6 aggregates (n=3) and primary human islets (n=2) in a static glucose stimulation assay. Glucose stimulation index shown in the top bar. f, Insulin secretion of hPSC-islets in a dynamic perfusion fusion assay. g, Electron microscopy showing ultrastructure of stage 6 beta cells and insulin granules. Scale bar, 2.5 μm. h, Glucagon secretion by hPSC-islets in a static glucose stimulation assay. Data obtained from one representative differentiation batch; n=3, technical replicates. (il) hPSC-islets ameliorated diabetes and improved overall survival when transplanted into diabetic mice. i, Left: Representative image of a nephrectomized kidney showing hPSC-islet grafts under the renal capsule. Scale bar, 0.1 cm. Center, Right: Hematoxylin & Eosin (H&E) histology of kidney sections showing hPSC-islet grafts and graft vascularization. Scale bar, 200 μm (center), 75 μm (right). j, Serial follow-up of body weight of hPSC-islet transplanted diabetic mice (n = 22). k, Blood glucose levels in response to IPGTT in healthy (n = 8) and STZ-induced diabetic mice with (n = 17) and without (n = 8) hPSC-islet transplantation at 16 wpt. l, Survival rate of STZ-induced diabetic mice with or without hPSC-islet transplantation. All data are presented as mean ± SEM. [Figure 6]Figure 6 shows the established differentiation protocol stably performed across hPSC lines. Similar marker expression patterns and hyperglycemia reversal ability were observed across three other hPSC lines subjected to the established differentiation protocol. a, Representative flow cytometry of pancreatic development markers during differentiation showed similar distribution and efficiency along the progression stages across three other hPSC lines. b, Representative immunofluorescence staining of islet hormones of hPSC-islet sections derived from three other independent hPSC lines. Scale bar, 50 μm. c. Long-term tracking of fasting blood glucose (left) and body weight (right) in diabetic mice transplanted with hPSC islets derived from three other independent hPSC lines showing consistent reversal of diabetes. d. Long-term tracking of fasting human C-peptide secretion in non-diabetic mice. Data presented as mean ± SEM. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0025] The present disclosure will be described below with reference to the embodiments shown in the accompanying drawings. However, it should be understood that the description is provided for illustrative purposes only, and not to limit the present disclosure. In addition, the following description will omit descriptions of known structures and techniques so as not to unnecessarily obscure the concepts of the present disclosure.

[0026] definition Unless otherwise stated, terms or expressions shall have the following definitions or meanings.

[0027] Pluripotent stem cells (PSCs) are undifferentiated cells defined by their ability to both self-renew and differentiate at the single cell level. Stem cells can produce progeny cells, including self-renewing progenitor cells, non-replicating progenitor cells, and terminally differentiated cells. Stem cells can be characterized by their ability to differentiate into functional cells of various cell lineages from multiple germ layers (endoderm, mesoderm, and ectoderm).

[0028] Differentiation is the process by which an unspecialized ("uncommitted") or less specialized cell acquires the characteristics of a specialized cell, e.g., a nerve or muscle cell. A differentiated cell is one that has adopted a more specialized ("committed") position within the lineage of a cell.

[0029] The term "committed" when applied to the process of differentiation refers to cells that have progressed in a differentiation pathway to a point where, under normal circumstances, they will continue to differentiate into a particular cell type or subset of cell types and, under normal circumstances, are unable to differentiate into a different cell type or revert to a less differentiated cell type.

[0030] In this context, "hPSC-islets" refers to pancreatic islets comprising C-peptide positive cells, glucagon positive cells and somatostatin positive cells derived from human pluripotent stem cells, eg, by the present methods.

[0031] "Marker" as used herein is a nucleic acid or polypeptide molecule that is differentially expressed in a cell of interest so that it can be used to indicate a particular state (such as developmental stage), characteristic properties and / or identity of the cell.In this context, differential expression refers to an increased level for a positive marker and a decreased level for a negative marker compared to an undifferentiated cell or a cell at another stage of differentiation.The detectable level of a marker nucleic acid or polypeptide is sufficiently high or low in a cell of interest compared to other cells, so that the cell of interest can be identified and distinguished from other cells using any of a variety of methods known in the art.

[0032] As used herein, a cell is "positive" or "positive" or "+" for a particular marker if the particular marker exceeds the detection limit and is significant enough in the cell. The appropriate detection limit can be determined by those skilled in the art depending on the test method. In particular, positivity by flow cytometry ("FC") is usually greater than about 2%. Positivity by polymerase chain reaction flow cytometry ("PCR") is usually about 35 cycles (Ct) or less.

[0033] As used herein, "suspension culture" refers to a culture of cells, single cells or clusters suspended in medium rather than attached to a surface, as opposed to adherent cultures such as plate cultures. One or more of the culture steps of the method can include suspension culture or plate culture. For example, plate culture is performed in steps 1, 2 and 3 of the method, and suspension culture is performed in steps 4, 5 and 6 of the method. The culture steps are described in more detail in the following sections and examples.

[0034] Cultivation method and culture medium In attempts to recapitulate the differentiation of pluripotent stem cells into functional pancreatic endocrine cells in in vitro cell cultures, the differentiation process is often considered to proceed through multiple successive steps. With reference to FIG. 1(a), in particular, the differentiation process is generally considered to proceed through multiple steps, and in this stepwise differentiation, "step 1" or "step (1)" refers to the first step in the differentiation process, i.e., the differentiation of pluripotent stem cells into cells expressing markers characteristic of definitive endoderm. "Step 2" or "step (2)" refers to the second step, i.e., the differentiation of cells expressing markers characteristic of definitive endoderm into cells expressing markers characteristic of primitive gut cells. Step "step 3" or "(3)" refers to the third step, i.e., the differentiation of cells expressing markers characteristic of primitive gut cells into cells expressing markers characteristic of posterior foregut cells. "Stage 4" or "step (4)" refers to the fourth step, i.e., differentiation of cells expressing markers characteristic of posterior foregut cells into cells expressing markers characteristic of pancreatic progenitor cells. "Stage 5" or "step (5)" refers to the fifth step, i.e., differentiation of cells expressing markers characteristic of pancreatic progenitor cells into cells expressing markers characteristic of pancreatic endocrine precursor cells. "Stage 6" or "step (6)" refers to the sixth step, i.e., differentiation of cells expressing markers characteristic of pancreatic endocrine precursor cells into cells expressing markers characteristic of functional hPSC-islets.

[0035] As used herein, a "functional hPSC-islet" is a pancreatic islet derived from a human pluripotent stem cell and having one or more functional characteristics similar or identical to those of a naturally occurring islet in a normal pancreas. One representative function of a functional islet is to secrete hormones, etc. The functional hPSC-islet of the present disclosure can secrete C-peptide, + Cells, Glucagon + Cells and Somatostatin +The functional hPSC-islet of the present disclosure can be characterized as containing the main pancreatic endocrine cells, including cells.Therefore, the functional hPSC-islet of the present disclosure can be used to treat, alleviate or reverse the disease or symptoms caused by or related to the dysfunction or deficiency of the islet of Langerhans, for example, T1DM.

[0036] As used herein, the term "treat", "treating" or "treatment" refers to the control, amelioration or cure of a disease or condition or one or more symptoms or complications thereof in a subject, including the alleviation of symptoms or complications, the delay in the progression of the disease or condition, or the complete cure of the disease or condition. In some embodiments, the term "treat", "treating" or "treatment" includes prophylactic purposes administered prior to the onset or onset of a disease or condition or one or more symptoms or complications thereof. Effective treatment can be determined by measuring physiological parameters, observing morphology, or by any means known or developed in the art for the same purpose. In the context of islet transplantation, effective treatment can be represented by the restoration of endogenous insulin secretion and improved glycemic control, which can be characterized by one or more of the following: reduced fasting blood glucose levels, reduced preprandial blood glucose levels, reduced HbA1c levels, reduced need for exogenous insulin, sustained postprandial C-peptide release. For example, according to an embodiment of the present disclosure, the inventors have demonstrated that transplantation of human pluripotent stem cell-derived islets effectively restores endogenous insulin secretion and improves glycemic control in recipients. After intraportal infusion of one dose of stem cell-derived islets, fasting blood glucose levels and mean pre-prandial blood glucose levels were significantly reduced in all recipients. For example, the recipient's mean HbA1c may be reduced by at least 1%, preferably at least 2%, after transplantation, e.g., 3 months after transplantation, compared to pre-transplant levels. For example, the mean supplement of exogenous insulin is reduced by at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50% after transplantation, e.g., 3 months after transplantation. In one specific embodiment, at 3 months after transplantation, the mean HbA1c was reduced by more than 2% compared to peak values, while the mean exogenous insulin requirement was reduced by 46%. Furthermore, sustained C-peptide release in response to a meal was observed in all recipients.Notably, these improvements were also observed in recipient macaques with glycemic conditions similar to those of unstable diabetic patients, in whom islet replacement therapy confers significant clinical and potentially life-saving benefits.

[0037] As used herein, the term diabetes refers to a syndrome that may be characterized by metabolic disorders that result in abnormally high blood glucose levels (hyperglycemia). The two most common forms of diabetes result from either a diminished production of insulin (type 1) or a diminished response of the body to insulin (type 2 and gestational). Type 1 diabetes (type 1 diabetes, type I diabetes mellitus (T1DM), insulin-dependent diabetes mellitus (IDDM), juvenile diabetes) is a disease that results in the permanent destruction of insulin-producing beta cells in the pancreas. Type 2 diabetes (non-insulin-dependent diabetes mellitus (NIDDM), or adult-onset diabetes) is a metabolic disorder that is primarily characterized by insulin resistance (a diminished response by the body to insulin), relative insulin deficiency, and hyperglycemia. Complications associated with diabetes include, but are not limited to, hypoglycemia, ketoacidosis, or nonketotic hyperosmolar coma, cardiovascular disease, renal failure, retinal damage, nerve damage, and microvascular damage. In some embodiments, the mammal is pre-diabetic, which can be characterized, for example, as having elevated fasting blood glucose or elevated post-prandial blood glucose.

[0038] According to a first aspect of the present disclosure, there is provided a method of generating functional hPSC-islets in vitro, the method comprising: (1) culturing the hPSCs in a sixth culture medium to obtain cells expressing markers characteristic of definitive endoderm; (2) culturing the cells obtained in step (1) in a fifth culture medium to obtain cells expressing markers characteristic of primitive intestinal cells; (3) culturing the cells obtained in step (2) in a fourth culture medium to obtain cells expressing markers characteristic of posterior foregut cells; (4) culturing the cells obtained in step (3) in a third culture medium to obtain cells expressing markers characteristic of pancreatic progenitor cells; (5) culturing the cells obtained in step (4) in a second culture medium to obtain cells expressing markers characteristic of pancreatic endocrine precursor cells; (6) culturing the cells obtained in step (5) in a first culture medium to obtain cells expressing markers characteristic of functional hPSC-islets; The second culture medium contains ISX9 or Wnt-C59.

[0039] In a preferred embodiment, the second culture medium comprises ISX9.

[0040] In a further embodiment, the second culture medium comprises a combination of ISX9 and Wnt-C59 small molecules.

[0041] The medium of the present application includes basal medium. The term "basal medium" as used herein refers to a composition that provides nutrients such as amino acids, vitamins, carbohydrates and salts that support cell survival and growth. In most cases, basal medium alone is insufficient to support cell growth, so supplements are usually added to the basal medium to provide cells with compounds essential for cell growth and / or differentiation. Exemplary basal media suitable for culturing mammalian stem cells are known in the art and include, but are not limited to, Dulbecco's Modified Eagle Medium (DMEM) or DMEM-derived media, such as DMEM basic, DMEM / F12, knockout DMEM (KO-DMEM), MCBD, RPMI 1640, CMRL1066, and the like.

[0042] The basal medium can be supplemented with nutrients according to the type of cultured cells. Supplementary nutrients can include commercially available premixes or can be formulated as needed. Exemplary nutritional supplements include, but are not limited to, B27 supplement, FBS (fetal bovine serum), BSA, N2 and GlutaMAX.

[0043] For example, B27 supplement or BSA is added to the basal medium at any stage of the present application. Preferably, B27 is added in an amount of 0.01-10%, more preferably 0.5-2%, such as 0.5%, 0.75%, 1%, 1.5%, 2%, most preferably 1%, or in an amount recommended by the manufacturer. In some cases, B27 supplement can be replaced with BSA or FBS in an equivalent amount.

[0044] For example, MCBD 131 can be added to the medium.

[0045] Depending on the culture stage, one or more differentiation agents may be included in the medium to induce cell differentiation. As used herein, "differentiation agent" refers to any agent that promotes the development of hPSCs into functional hPSC-islets. Differentiation agents in this application may include growth factors such as KGF and EGF. Differentiation agents may function by improving or increasing the production or growth of desired cell types and / or inhibiting or reducing the production or growth of one or more undesirable cell types by known or unknown mechanisms. The present invention is based at least on the unexpected that small molecules, specifically ISX9 and / or Wnt-C59, promote the differentiation of hPSCs into pancreatic islets, especially during the terminal differentiation of pancreatic endocrine precursor cells. Figure 1a shows a specific embodiment of a preferred combination of differentiation agents used in each stage of the culture method of the present invention.

[0046] Those skilled in the art will also understand that the use of a particular type of product is not essential to the present application. Any basal medium or nutritional supplement can be substituted with a functional alternative.

[0047] First Culture Medium (Step 6) The first culture medium comprises a basal medium supplemented with one or more differentiation agents selected from an ALK inhibitor, an adenylyl cyclase activator, an Axl inhibitor, an IκB kinase inhibitor, thyroid hormone and ZnSO4. (Step 6) In a preferred embodiment, the first culture medium comprises a basal medium supplemented with a combination of an ALK5 inhibitor, an adenylyl cyclase activator, an Axl inhibitor, an IκB kinase inhibitor, thyroid hormone and ZnSO4.

[0048] In some embodiments, the ALK inhibitor can be an ALK5 inhibitor that selectively inhibits ALK5, such as ALK5 inhibitor II, 616452, RepSox (E-616452), SB431542, and A83-01. The ALK inhibitor, such as ALK5 inhibitor II, is added in an amount of about 1-50 μM, preferably about 5-15 μM, or more preferably about 10 μM.

[0049] In some embodiments, the adenylyl cyclase activator is forskolin. The adenylyl cyclase activator, such as forskolin, is added in an amount of about 1-100 μM, preferably about 5-15 μM, or more preferably about 10 μM.

[0050] In some embodiments, the Axl inhibitor is R428 or an analog thereof. The Axl inhibitor, such as R428, is added in an amount of about 0.1-10 μM, preferably about 0.1-1 μM, or more preferably about 0.5 μM.

[0051] In some embodiments, the IκB kinase inhibitor is N-acetylcysteine ​​or an analog thereof. The IκB kinase inhibitor, such as N-acetylcysteine ​​or an analog thereof, is added in an amount of about 0.5 to 20 mM, preferably about 1 to 5 mM, or more preferably about 2 mM.

[0052] In some embodiments, the thyroid hormone is liothyronine sodium (T3). The thyroid hormone, such as T3, is added in an amount of about 0.1-20 μM, preferably about 0.5-1.5 μM, or more preferably about 1 μM.

[0053] In some embodiments, the first culture medium is a basal medium supplemented with ALK5 inhibitor II, forskolin, R428, N-acetylcysteine, T3 and ZnSO4.

[0054] In some embodiments, the first culture medium is further supplemented with at least one of B27, heparin, and vitamin C. B27 in the first culture medium can be replaced with a functionally equivalent amount of BSA or FBS.

[0055] In a preferred embodiment, the first culture medium comprises, in addition to a basal medium, one or more of about 1-50 μM ALK5 inhibitor II, about 0.1-10 μM R428, about 0.1-20 μM T3, about 1-100 μM forskolin, about 1-100 μM ZnSO4, and about 0.5-20 mM N-acetylcysteine.

[0056] In a preferred embodiment, the first culture medium contains, in addition to the basal medium, about 5-15 μM ALK5 inhibitor II, about 0.1-1 μM R428, about 0.5-1.5 μM T3, about 5-15 μM forskolin, about 5-15 μM ZnSO4, and / or about 1-5 mM N-acetylcysteine.

[0057] In some embodiments, the first culture medium comprises, in addition to basal medium, about 0.5%-2% B27, about 5-15 μM ALK5 inhibitor II, about 0.1-1 μM R428, about 0.5-1.5 μM T3, about 5-15 μM forskolin, about 5-15 μg / mL heparin, about 5-15 μM ZnSO4, about 1-5 mM N-acetylcysteine, and / or about 0.1-0.5 mM vitamin C.

[0058] In some embodiments, the first culture medium contains about 1% B27, about 10 μM ALK5 inhibitor II, about 0.5 μM R428, about 1 μM T3, about 10 μM forskolin, about 10 μg / mL heparin, about 10 μM ZnSO4, about 2 mM N-acetylcysteine, and / or about 0.25 mM vitamin C.

[0059] In a preferred embodiment, the culturing in step 6 of the method is carried out in suspension for about 2-6 days using the first culture medium to generate pancreatic islets from the pancreatic endocrine precursor cells.

[0060] Second Culture Medium (Step 5) Pancreatic endocrine precursor cells are obtained by culturing the pancreatic precursor cells in a second culture medium containing isoxazole 9 (ISX9) or preferably a combination of ISX9 and a Wnt signaling inhibitor as a differentiation agent (step 5).

[0061] ISX9 is added in an amount of about 0.5 to 200 μM, preferably about 0.5 to 100 μM, and more preferably about 10 μM.

[0062] Inhibitors of Wnt signaling, such as Wnt-C59, are added in an amount of about 5 to 2000 nM, more preferably about 10 to 500 nM, more preferably about 50 to 250 nM, or even more preferably about 100 nM.

[0063] In some embodiments, the second culture medium is further supplemented with one or more differentiation agents selected from the group consisting of an ALK inhibitor, a BMP signaling inhibitor, a thyroid hormone, and an inhibitor of NOTCH signaling. (Step 5)

[0064] For example, the inhibitor of the ALK inhibitor is an ALK5 inhibitor, which may be an ALK5 inhibitor that selectively inhibits ALK5, such as ALK5 inhibitor II, 616452, RepSox (E-616452), SB431542, and A83-01. The ALK inhibitor, for example, ALK5 inhibitor II, is added in an amount of about 1 to 50 μM, preferably about 5 to 15 μM, or more preferably about 10 μM.

[0065] For example, a BMP (bone morphogenetic protein) signaling inhibitor is LDN193189. The BMP signaling inhibitor, for example, LDN193189, is added in an amount of about 0.015 to 10 μM, preferably about 0.05 to 5 μM, more preferably about 0.1 to 1 μM, or even more preferably about 0.3 μM.

[0066] For example, the thyroid hormone is T3. The thyroid hormone, for example T3, is added in an amount of about 0.05 to 50 μM, preferably about 0.1 to 10 μM, more preferably 0.5 to 5 μM, and even more preferably about 1 μM.

[0067] For example, the inhibitor of NOTCH signaling is Xxi. The inhibitor of NOTCH signaling, for example, Xxi, is added in an amount of about 0.005 to 2 μM, preferably about 0.05 to 1 μM, or more preferably about 0.1 μM.

[0068] In some embodiments, the second culture medium is further supplemented with a ROCK inhibitor, such as Y27632. The ROCK inhibitor, such as Y27632, is added in an amount of about 0.5 to 200 μM, preferably about 0.4 to 100 μM, or more preferably about 10 μM.

[0069] In some embodiments, the second culture medium is further supplemented with one or more of L-glutamine, such as Glutamax, B27, heparin, and vitamin C.

[0070] In some embodiments, the basal medium of the second culture medium is DMEM basic medium or MCBD medium.

[0071] In some embodiments, the second culture medium contains, in addition to basal medium, about 0.01% to 10% B27, about 0.5 to 200 μM ALK5 inhibitor II, about 0.015 to 6 μM LDN193189, about 0.05 to 20 μM T3, about 0.5 to 200 μM ISX9, about 0.5 to 200 μg / mL heparin, about 0.005 to 2 μM Notch inhibitor Xxi, about 5 to 2000 nM Wnt-C59, about 0.5 to 200 μM Y27632, and about 0.0125 to 5 mM Vitamin C; and optionally about 0.05% to 20% Glutamax.

[0072] In some embodiments, the second culture medium contains, in addition to basal medium, preferably 1% Glutamax, about 0.025x-5x B27, about 0.5-100 μM ALK5 inhibitor II, about 0.015-10 μM LDN193189, about 0.05-50 μM T3, about 0.5-100 μM ISX9, about 0.5-100 μg / mL heparin, about 0.005-2 μM gamma-secretase inhibitor Xxi, about 5-2000 nM Wnt-C59, about 0.5-200 μM Y27632, and / or about 0.0125-5 mM vitamin C; and optionally about 0.05%-5% Glutamax.

[0073] In some embodiments, the second culture medium contains, in addition to basal medium, about 1% B27, about 10 μM ALK5 inhibitor II, about 0.3 μM LDN193189, about 1 μM T3, about 10 μM ISX9, about 10 μg / mL heparin, about 0.1 μM gamma-secretase inhibitor Xxi, about 100 nM Wnt-C59, about 10 μM Y27632, and / or about 0.25 mM vitamin C; optionally, about 1% Glutamax.

[0074] In a preferred embodiment, the culture in step 5 of the method is carried out in suspension using the second culture medium for about 3 to 10 days, particularly about 4 to 6 days, to generate pancreatic endocrine precursor cells from the pancreatic progenitor cells.

[0075] Third Culture Medium (Step 4) In some embodiments, pancreatic progenitor cells are obtained by culturing the posterior foregut in a third culture medium comprising basal medium supplemented with one or more differentiation agents selected from the group consisting of growth factors such as epidermal growth factor (EGF), B complex vitamins such as nicotinamide, activators of protein kinase C such as TPB, and inhibitors of sonic hedgehog signaling such as Sant1 (step 4).

[0076] In some embodiments, pancreatic progenitor cells are obtained by culturing the posterior foregut in a third culture medium supplemented with one or more of EGF, nicotinamide, TPB and Sant1, preferably a combination of EGF, nicotinamide, TPB and Sant1.

[0077] For example, a growth factor such as EGF is added in an amount of about 1-2000 ng / mL, preferably about 5-500 ng / mL, more preferably about 10-200 ng / mL, or even more preferably 100 ng / mL.

[0078] For example, a B complex vitamin, such as nicotinamide, is added in an amount of about 0.5-200 mM, preferably about 1-100 mM, more preferably about 5-50 mM, or even more preferably about 10 mM.

[0079] For example, a protein kinase C activator, such as TPB, is added in an amount of about 0.01 to 10 μM, preferably about 0.02 to 5 μM, more preferably about 0.1 to 1 μM, or even more preferably about 0.2 μM.

[0080] For example, an inhibitor of sonic hedgehog signaling, such as Sant1, is added in an amount of about 0.0125 to 5 μM, preferably about 0.025 to 1 μM, more preferably about 0.05 to 0.5 μM, or even more preferably about 0.25 μM.

[0081] In some embodiments, the third culture medium is further supplemented with one or more of L-glutamine, such as Glutamax, B27, and Vitamin C.

[0082] In some embodiments, the basal medium of the third culture medium is DMEM basic medium.

[0083] In some embodiments, the third culture medium contains, in addition to the basal medium, about 0.01%-10% B27, about 5-2000 ng / mL EGF, about 0.01-4 μM TPB, about 0.5-200 mM nicotinamide, about 0.0125-5 μM Sant1, and about 0.0125-5 mM Vitamin C; and optionally about 0.05%-20% Glutamax.

[0084] In some embodiments, the third culture medium contains, in addition to the basal medium, about 0.01%-10% B27, about 1-500 ng / mL EGF, about 0.01-10 μM TPB, about 0.5-200 mM nicotinamide, about 0.0125-5 μM Sant1 and / or about 0.0125-5 mM Vitamin C; and optionally about 0.05%-20% Glutamax.

[0085] In some embodiments, the third culture medium contains, in addition to basal medium, about 1% B27, about 100 ng / mL EGF, about 0.2 μM TPB, about 10 mM nicotinamide, about 0.25 μM Sant1 and / or about 0.25 mM vitamin C; and optionally about 1% Glutamax.

[0086] In a preferred embodiment, the culture in step 4 of the method is carried out in suspension using a third culture medium for about 4-7 days, preferably 5-6 days, to generate pancreatic progenitor cells from the posterior foregut duct.

[0087] Fourth Culture Medium (Step 3) In some embodiments, the posterior foregut tube is obtained by culturing the primitive gut tube in a fourth culture medium comprising basal medium supplemented with an inhibitor of Wnt signaling, such as Wnt-C59, as a differentiation agent (Step 3).

[0088] Inhibitors of Wnt signaling, such as Wnt-C59, are added in an amount of about 5 to 2000 nM, more preferably about 10 to 500 nM, more preferably about 50 to 250 nM, or even more preferably about 100 nM.

[0089] In a further embodiment, the fourth culture medium is further supplemented with one or more differentiation agents selected from the group consisting of retinoic acid (RA), an inhibitor of sonic hedgehog signaling (such as Sant1), and an inhibitor of BMP signaling (such as LDN193189).

[0090] In some embodiments, the posterior foregut is obtained by culturing the primitive gut in a fourth culture medium supplemented with Wnt-C59 and one or more of retinoic acid (RA), Sant1, and LDN193189, preferably a combination of retinoic acid (RA), Sant1, LDN193189, and Wnt-C59.

[0091] For example, retinoic acid (RA) is added in an amount of about 0.1 to 40 μM, preferably about 0.5 to 10 μM, more preferably about 1 to 5 μM, or even more preferably about 2 μM.

[0092] For example, an inhibitor of sonic hedgehog signaling, such as Sant1, is added in an amount of about 0.0125 to 5 μM, preferably about 0.025 to 1 μM, more preferably about 0.05 to 0.5 μM, or even more preferably about 0.25 μM.

[0093] For example, a BMP signaling inhibitor, such as LDN193189, is added in an amount of about 0.01 to 2 μM, preferably about 0.05 to 1 μM, or more preferably about 0.1 μM.

[0094] In some embodiments, the basal medium of the fourth culture medium is DMEM basic medium.

[0095] In some embodiments, the fourth culture medium contains, in addition to the basal medium, about 0.01% to 10% B27, about 0.1 to 40 μM retinoic acid, about 0.05 to 2 μM LDN193189, about 0.0125 to 5 μM Sant1 and / or about 5 to 2000 nM Wnt-C59.

[0096] In some embodiments, the fourth culture medium comprises, in addition to basal medium, about 1% B27, about 2 μM retinoic acid, about 0.1 μM LDN193189, about 0.25 μM Sant1 and / or about 100 nM Wnt-C59.

[0097] In a preferred embodiment, the culture in step 3 of the method is carried out for about 2 to 7 days, such as 2, 3, 4, 5, 6 or 7 days, using a fourth culture medium to generate a posterior foregut tube from the primitive gut tube.

[0098] Fifth Culture Medium (Step 2) In some embodiments, the primitive gut tube is obtained by culturing the definitive endoderm in a fifth culture medium comprising a basal medium supplemented with one or more differentiation agents selected from the group consisting of fibroblast growth factors such as KGF, FGF2 and / or FGF10, TGF-β / Smad inhibitors such as SB431542, and / or Wnt inhibitors such as Wnt-C59 (Step 2).

[0099] In some embodiments, the primitive gut tube is obtained by culturing definitive endoderm in a fifth culture medium supplemented with KGF.

[0100] In some embodiments, the primitive gut tube is obtained by culturing definitive endoderm in a fifth culture medium supplemented with KGF, SB431542 and Wnt-C59.

[0101] For example, a growth factor such as KGF is added in an amount of about 2.5 to 1000 ng / mL, preferably about 5 to 500 ng / mL, more preferably about 10 to 100 ng / mL, or even more preferably about 50 ng / mL.

[0102] For example, a TGF-β / Smad inhibitor such as SB431542 is added in an amount of about 0.25 to 100 μM, preferably about 0.5 to 50 μM, more preferably about 1 to 10 μM, or even more preferably about 5 μM.

[0103] Inhibitors of Wnt signaling, such as Wnt-C59, are added in an amount of about 5 to 2000 nM, more preferably about 10 to 500 nM, more preferably about 50 to 250 nM, or even more preferably about 100 nM.

[0104] In some embodiments, the basal medium of the fifth culture medium is MCBD 131 medium.

[0105] In some embodiments, the fifth culture medium contains, in addition to the basal medium, about 0.225-90 mM glucose, about 0.025%-10% BSA or 0.01%-10% B27, about 2.5-1000 ng / mL KGF, about 0.0125-5 mM Vitamin C, about 0.25-100 μM SB431542 and / or about 5-2000 nM Wnt-C59; and optionally about 0.05%-20% Glutamax.

[0106] In some embodiments, the fifth culture medium contains, in addition to basal medium, about 4.5 mM glucose, about 0.5% BSA or 1% B27, about 50 ng / mL KGF, about 0.25 mM Vitamin C, about 5 μM SB431542 and / or about 100 nM Wnt-C59; and optionally about 1% Glutamax.

[0107] In a preferred embodiment, the culture in step 2 of the method is carried out for about 1 to 4 days, such as 1, 2, 3 or 4 days, using a fifth culture medium to generate a primitive gut tube from the definitive endoderm.

[0108] Sixth Culture Medium (Step 1) In some embodiments, the method comprises culturing pluripotent stem cells in a sixth culture medium comprising a basal medium supplemented with one or more differentiation agents selected from the group consisting of activin A, a Wnt activator such as Chir99021, a PI3K inhibitor such as PI103, and a ROCK inhibitor such as Y27632, and in a seventh culture medium comprising a basal medium optionally supplemented with activin A.

[0109] For example, activin A in the sixth or seventh medium is added in an amount of about 20 to 1000 ng / mL, preferably about 50 to 500 ng / mL, or more preferably about 100 ng / mL.

[0110] For example, a Wnt activator such as Chir99021 is added in an amount of about 0.3-120 μM, preferably 1-60 μM, more preferably 3-20 μM, or even more preferably about 6 μM.

[0111] For example, a PI3K inhibitor such as PI103 is added in an amount of about 2.5-1000 nM, preferably 5-500 nM, more preferably 10-100 nM, or even more preferably about 50 nM.

[0112] For example, a ROCK inhibitor such as Y27632 is added in an amount of about 0.5 to 200 μM, preferably about 0.4 to 100 μM, or more preferably about 10 μM.

[0113] In a further embodiment, the sixth culture medium further comprises one or more of glucose, Glutamax, B27, and Vitamin C.

[0114] In some embodiments, the basal medium of the sixth culture medium is MCBD 131 medium.

[0115] In some embodiments, definitive endoderm is obtained by culturing pluripotent stem cells in a sixth culture medium supplemented with about 0.225-90 mM glucose, about 0.01%-10% B27, about 20-1000 ng / mL activin A, about 0.0125-5 mM vitamin C, about 0.3-120 μM Wnt activator, about 2.5-1000 nM PI3K inhibitor and / or about 0.5-200 μM ROCK inhibitor; and optionally about 0.05%-20% Glutamax.

[0116] In another further embodiment, the seventh culture medium further comprises glucose, Glutamax, B27 and Vitamin C.

[0117] In some embodiments, the basal medium of the seventh culture medium is MCBD 131 medium.

[0118] In some embodiments, the method comprises culturing the pluripotent stem cells in a sixth culture medium supplemented with about 4.5 mM glucose, about 1% Glutamax, about 1% B27, about 100 ng / mL activin A, about 0.25 mM Vitamin C, about 6 μM Chir99021, about 50 nM PI103 and / or about 10 μM Y27632 for about 1 day, followed by culturing in a seventh culture medium supplemented with about 0.225-90 mM glucose, about 0.05%-20% Glutamax, about 0.01%-10% B27, about 5-2000 ng / mL activin A and / or about 0.0125-5 mM Vitamin C for about 2-4 days.

[0119] In some embodiments, the method comprises culturing the pluripotent stem cells in a sixth culture medium supplemented with about 4.5 mM glucose, about 1% Glutamax, about 1% B27, about 100 ng / mL activin A, about 0.25 mM Vitamin C, about 6 μM Chir99021, about 50 nM PI103 and / or about 10 μM Y27632 for about 1 day, then in a seventh culture medium supplemented with about 4.5 mM glucose, about 1% Glutamax, about 1% B27, about 100 ng / mL activin A and / or about 0.25 mM Vitamin C for about 3 days.

[0120] In some embodiments, pluripotent stem cells can be embryonic stem cells or induced pluripotent stem cells, for example chemically induced pluripotent stem cells.Embryonic stem cells can be commercially available embryonic stem cells.Embryonic stem cells can be derived from in vitro fertilized embryos.Embryonic stem cells can be obtained from embryos that have not developed in vivo and are within 14 days after fertilization.

[0121] In certain embodiments, the method includes (1) culturing pluripotent stem cells in a sixth culture medium supplemented with about 4.5 mM glucose, about 1% Glutamax, about 1% B27, about 100 ng / mL activin A, about 0.25 mM Vitamin C, about 6 μM Chir99021, about 50 nM PI103, and about 10 μM Y27632 for about 1 day, and then in a seventh culture medium supplemented with about 4.5 mM glucose, about 1% Glutamax, about 1% B27, about 100 ng / mL activin A, about 0.25 mM Vitamin C for about 3 days to obtain definitive endoderm. (2) culturing the definitive endoderm in a fifth culture medium containing about 4.5 mM glucose, about 1% Glutamax, about 1% B27, about 50 ng / mL KGF, about 0.25 mM vitamin C, about 5 μM SB431542, and about 100 nM Wnt-C59 for about 2 days to obtain a primitive gut; (3) culturing the primitive gut in a fourth culture medium containing about 1% B27, about 2 μM retinoic acid, about 0.1 μM LDN193189, about 0.25 μM Sant1, and about 100 nM Wnt-C59 for about 4 days to obtain a posterior foregut; (4) culturing the primitive gut in a fourth culture medium containing about 1% B27, about 2 μM retinoic acid, about 0.1 μM LDN193189, about 0.25 μM Sant1, and about 100 nM Wnt-C59 for about 4 days to obtain a posterior foregut. The intestine is suspension cultured for about 5 to 6 days in a third culture medium containing about 1% Glutamax, about 1% B27, about 100 ng / mL EGF, about 0.2 μM TPB, about 10 mM nicotinamide, about 0.25 μM Sant1, and about 0.25 mM vitamin C to obtain pancreatic progenitor cells; (5) the pancreatic progenitor cells are cultured in a third culture medium containing about 1% Glutamax, about 1% B27, about 10 μM ALK5 inhibitor II, about 0.3 μM LDN193189, about 1 μM T3, about 10 μM ISX9, about 10 μg / mL heparin, about 0.1 μM γ-secretase inhibitor X ... xi. Suspension culture in a second culture medium containing about 100 nM Wnt-C59, about 10 μM Y27632, and about 0.25 mM vitamin C for about 6 days to obtain pancreatic endocrine precursor cells; and (6) suspension culture of the pancreatic endocrine precursor cells in a first culture medium containing about 1% B27, about 10 μM ALK5 inhibitor II, about 0.5 μM R428, about 1 μM T3, about 10 μM forskolin, about 10 μg / mL heparin, about 10 μM ZnSO4, about 2 mM N-acetylcysteine, and about 0.25 mM vitamin C for about 2 to 4 days to obtain C-peptide.+ Cells, Glucagon + Cells and Somatostatin + The method includes obtaining functional hPSC-islets containing cells.

[0122] In a preferred embodiment of the first aspect, the method comprises administering to the subject a C-peptide + Cells, Glucagon + Cells and Somatostatin + Generate functional hPSC-islets containing cells.

[0123] According to an embodiment, the method provides for the extraction of NKX6.1 from human pluripotent stem cells (hPSCs) with an efficiency of up to approximately 70%. + C-peptide + The differentiation process produces relatively uniform, islet-sized aggregates containing approximately 90% PDX1 cells. + Pancreatic progenitor cells are generated by early stage 4 and finally by stage 6 with 90% CHGA + NGN3 - We demonstrated that the protocol generated endocrine cells. Notably, the protocol showed stable performance, with similar results consistently reproduced across differentiation batches. Collectively, these data demonstrated the establishment of a protocol that reliably promotes pancreatic endocrine differentiation from hPSCs.

[0124] hPSC-islets According to the second aspect of the present disclosure, a population of functional hPSC-islets is provided that can be obtained by the above-mentioned method.These populations of functional hPSC-islets can be used to treat, for example, mammals that have or are at risk of having type I diabetes, type II diabetes, pre-diabetes or any combination thereof, by transplanting these islets in subjects that need such treatment.

[0125] According to a third aspect of the present disclosure, there is provided a pharmaceutical composition comprising a population of functional hPSC-islets as described above.The pharmaceutical composition can be used, for example, to treat a mammal having or at risk of having type I diabetes, type II diabetes, pre-diabetes, or any combination thereof, by transplanting these islets in a subject in need of such treatment.

[0126] According to a fourth aspect of the present disclosure, there is provided a method for treating a mammal having or at risk of having type I diabetes, type II diabetes, prediabetes, or any combination thereof, comprising administering to the mammal a population of functional hPSC-islets as described above or a pharmaceutical composition as described above.

[0127] According to a fifth aspect of the present disclosure, there is provided a kit for generating functional hPSC-pancreatic islets, the kit including at least one of the above-mentioned first to sixth culture media.

[0128] According to a sixth aspect of the present disclosure, there is provided a combination of small molecules ISX9 and Wnt-C59 in inducing differentiation of pancreatic progenitor cells into pancreatic endocrine precursor cells.

[0129] EMBODIMENTS OF THE PRESENT DISCLOSURE 1. C-peptide + Cells, Glucagon + Cells and Somatostatin + 1. A method for generating functional human PSC-islets in vitro comprising: (1) culturing the hPSCs in a sixth culture medium to obtain cells expressing markers characteristic of definitive endoderm; (2) culturing the cells obtained in step (1) in a fifth culture medium to obtain cells expressing markers characteristic of the primitive gut; (3) culturing the cells obtained in step (2) in a fourth culture medium to obtain cells expressing markers characteristic of the posterior foregut tract; (4) culturing the cells obtained in step (3) in a third culture medium to obtain cells expressing markers characteristic of pancreatic progenitor cells; (5) culturing the cells obtained in step (4) in a second culture medium to obtain cells expressing markers characteristic of pancreatic endocrine precursor cells; (6) culturing the cells obtained in step (5) in a first culture medium to obtain cells expressing markers characteristic of functional hPSC-islets; The method, wherein the second culture medium is supplemented with ISX9 or Wnt-C59, preferably ISX9.

[0130] 2. The method of claim 1, wherein the second culture medium is supplemented with ISX9 and Wnt-C59.

[0131] 3. The method of embodiment 1 or embodiment 2, wherein the first culture medium comprises a basal medium supplemented with one or more of an ALK5 inhibitor, an adenylyl cyclase activator, an Axl inhibitor, an IκB kinase inhibitor, T3 and ZnSO4.

[0132] 4. The method of embodiment 3, wherein the ALK5 inhibitor is ALK5 inhibitor II or an analogue thereof.

[0133] 5. The method of embodiment 3 or embodiment 4, wherein the adenylyl cyclase activator is forskolin or an analogue thereof.

[0134] 6. The method of any one of embodiments 3-5, wherein the Axl inhibitor is R428 or an analogue thereof.

[0135] 7. The method of any one of embodiments 3 to 6, wherein the IκB kinase inhibitor is N-acetylcysteine ​​or an analogue thereof.

[0136] 8. The method of any one of embodiments 1-7, wherein the basal medium of the first culture medium is DMEM basic or MCBD131.

[0137] 9. The method of any one of embodiments 1-8, wherein the first culture medium is further supplemented with one or more of B27, heparin and vitamin C.

[0138] 10. The method of any one of embodiments 1 to 9, wherein the second culture medium comprises a basal medium further supplemented with one or more of an inhibitor of TGF-βRI, an inhibitor of BMP signaling, a thyroid hormone, and an inhibitor of NOTCH signaling.

[0139] 11. The method of embodiment 10, wherein the inhibitor of TGF-βRI is ALK5 inhibitor II.

[0140] 12. The method of embodiment 10 or embodiment 11, wherein the BMP signaling inhibitor is LDN193189.

[0141] 13. The method of any one of embodiments 10-12, wherein the thyroid hormone is T3.

[0142] 14. The method according to any one of embodiments 10 to 13, wherein the inhibitor of NOTCH signaling is a gamma-secretase inhibitor, such as Xxi.

[0143] 15. The method according to any one of embodiments 10 to 14, wherein the basal medium of the second culture medium is DMEM basic or MCBD131.

[0144] 16. The method of any one of embodiments 10-15, wherein the second culture medium is further supplemented with one or more of L-glutamine, B27, heparin, Y27632 and vitamin C.

[0145] 17. The method of any one of embodiments 1-16, wherein the third culture medium comprises a basal medium supplemented with one or more of epidermal growth factor, an activator of protein kinase C, an inhibitor of sonic hedgehog signaling, and a vitamin B complex component.

[0146] 18. The method of embodiment 17, wherein the epidermal growth factor is EGF.

[0147] 19. The method of embodiment 17 or embodiment 18, wherein the activator of protein kinase C is TPB.

[0148] 20. The method of any one of embodiments 17-19, wherein the inhibitor of Sonic Hedgehog signaling is Sant1.

[0149] 21. The method of any one of embodiments 17-20, wherein the component of the vitamin B complex is nicotinamide.

[0150] 22. The method of any one of embodiments 17-21, wherein the basal medium of the third culture medium is DMEM basic or MCBD131.

[0151] 23. The method of any one of embodiments 17-22, wherein the third culture medium is further supplemented with one or more of L-glutamine, B27 and vitamin C.

[0152] 24. The method of any one of embodiments 1 to 23, wherein the fourth culture medium is supplemented with one or more of retinoic acid (RA), an inhibitor of sonic hedgehog signaling, and an inhibitor of BMP signaling.

[0153] 25. The method of embodiment 24, wherein the inhibitor of Sonic Hedgehog signaling is Sant1.

[0154] 26. The method of embodiment 24 or embodiment 25, wherein the inhibitor of BMP signaling is LDN193189.

[0155] 27. The method according to any one of embodiments 24 to 26, wherein the fourth culture medium is further supplemented with an inhibitor of Wnt signaling.

[0156] 28. The method of embodiment 27, wherein the inhibitor of Wnt signaling is Wnt-C59.

[0157] 29. The method of any one of embodiments 24 to 28, wherein the basal medium of the fourth culture medium is DMEM basic or MCBD131.

[0158] 30. The method of any one of embodiments 24 to 29, wherein the fourth medium is further supplemented with B27.

[0159] 31. The method according to any one of embodiments 1 to 30, wherein the fifth culture medium comprises a basal medium supplemented with an activator of FGF signaling.

[0160] 32. The method of embodiment 31, wherein the activator of FGF signaling is FGF2, FGF10 or KGF.

[0161] 33. The method according to embodiment 31 or embodiment 32, wherein the fifth culture medium is further supplemented with a TGF-β / Smad inhibitor and / or a Wnt inhibitor.

[0162] 34. The method of any one of embodiments 33, wherein the TGF-β / Smad inhibitor is SB431542.

[0163] 35. The method of embodiment 33 or 34, wherein the Wnt inhibitor is Wnt-C59.

[0164] 36. The method of any one of embodiments 31 to 35, wherein the basal medium of the fifth culture medium is DMEM basic or MCBD131.

[0165] 37. The method of any one of embodiments 31-36, wherein the fifth culture medium is further supplemented with one or more of glucose, L-glutamine, B27 or BSA, KGF and vitamin C.

[0166] 38. The method of any one of embodiments 1 to 36, wherein the sixth culture medium comprises a basal medium supplemented with one or more of an activator of an activin receptor, a Wnt activator, a ROCK inhibitor, and a PI3K inhibitor.

[0167] 39. The method of embodiment 38, wherein the activator of the activin receptor is activin A.

[0168] 40. The method of embodiment 38-39, wherein the Wnt activator is Chir99021.

[0169] 41. The method of any one of embodiments 38 to 40, wherein the ROCK inhibitor is Y27632.

[0170] 42. The method of any one of embodiments 38-41, wherein the PI3K inhibitor is PI103.

[0171] 43. The method of any one of embodiments 38 to 42, wherein the basal medium of the sixth culture medium is DMEM basic medium or MCBD131 medium.

[0172] 44. The method of any one of embodiments 38-43, wherein the sixth culture medium is further supplemented with one or more of glucose, L-glutamine, B27, vitamin C.

[0173] 45. The method according to any one of embodiments 1 to 44, wherein step (1) further comprises culturing in a seventh culture medium after culturing in the sixth culture medium and before step (2), and the seventh culture medium comprises a basal medium supplemented with glucose, L-glutamine, B27, activin A and vitamin C.

[0174] 46. ​​The method of embodiment 45, comprising culturing the pluripotent stem cells for about 1 day in a sixth culture medium supplemented with about 4.5 mM glucose, about 1% Glutamax, about 1% B27, about 100 ng / mL activin A, about 0.25 mM Vitamin C, about 6 μM Chir99021, about 50 nM PI103 and about 10 μM Y27632, followed by culturing the pluripotent stem cells for about 3 days in a seventh culture medium supplemented with about 4.5 mM glucose, about 1% Glutamax, about 1% B27, about 100 ng / mL activin A and / or about 0.25 mM Vitamin C.

[0175] 47. The method according to any one of embodiments 1 to 46, wherein the human pluripotent stem cells are embryonic stem cells or induced pluripotent stem cells.

[0176] 48. The method according to any one of the preceding embodiments, wherein the culture of one or more of steps (1) to (6) is a suspension culture.

[0177] 49. The method according to embodiment 48, wherein the culture in steps (1) to (3) is a suspension culture.

[0178] 50. A population of cells comprising functional hPSC-islets obtainable by a method according to any one of embodiments 1 to 49.

[0179] 51. A pharmaceutical composition comprising a population of cells according to embodiment 50.

[0180] 52. A method for treating a mammal having or at risk of having type I diabetes, type II diabetes, prediabetes, or any combination thereof, comprising administering to the mammal a population of cells described in embodiment 50 or a pharmaceutical composition described in embodiment 51.

[0181] 53. C-peptide + Cells, Glucagon + Cells and Somatostatin + A kit for generating functional human PSC-islets containing cells, comprising: A kit comprising at least one of the first to seventh culture media defined in any one of embodiments 1 to 49.

[0182] 54. C-peptide + Cells, Glucagon + Cells and Somatostatin + 1. A method for generating functional human PSC-islets in vitro comprising: culturing the pluripotent stem cells in a sixth culture medium supplemented with about 4.5 mM glucose, about 1% Glutamax, about 1% B27, about 100 ng / mL activin A, about 0.25 mM vitamin C, about 6 μM Chir99021, about 50 nM PI103, and about 10 μM Y27632 for about 1 day, then in a seventh culture medium supplemented with about 4.5 mM glucose, about 1% Glutamax, about 1% B27, about 100 ng / mL activin A, about 0.25 mM vitamin C for about 3 days to obtain definitive endoderm; culturing the definitive endoderm in a fifth culture medium containing about 4.5 mM glucose, about 1% Glutamax, about 0.5% BSA or 1% B27, about 50 ng / mL KGF, about 0.25 mM Vitamin C, about 5 μM SB431542 and about 100 nM Wnt-C59 for about 2 days to obtain a primitive gut tube; culturing the primitive gut in a fourth culture medium containing about 1% B27, about 2 μM retinoic acid, about 0.1 μM LDN193189, about 0.25 μM Sant1 and about 100 nM Wnt-C59 for about 4 days to obtain a posterior foregut; Culturing the posterior foregut tract in a third culture medium containing about 1% Glutamax, about 1% B27, about 100 ng / mL EGF, about 0.2 μM TPB, about 10 mM nicotinamide, about 0.25 μM Sant1, and about 0.25 mM vitamin C for about 5 to 6 days to obtain pancreatic progenitor cells; culturing the pancreatic progenitor cells in a second culture medium containing about 1% Glutamax, about 1% B27, about 10 μM ALK5 inhibitor II, about 0.3 μM LDN193189, about 1 μM T3, about 10 μM ISX9, about 10 μg / mL heparin, about 0.1 μM γ-secretase inhibitor Xxi, about 100 nM Wnt-C59, about 10 μM Y27632 and about 0.25 mM vitamin C for about 6 days to obtain pancreatic endocrine progenitor cells; The pancreatic endocrine precursor cells are cultured for about 2 to 6 days in a first culture medium containing about 1% B27, about 10 μM ALK5 inhibitor II, about 0.5 μM R428, about 1 μM T3, about 10 μM forskolin, about 10 μg / mL heparin, about 10 μM ZnSO4, about 2 mM N-acetylcysteine, and about 0.25 mM vitamin C medium, and C-peptide is administered. + Cells, Glucagon + Cells and Somatostatin + obtaining functional hPSC-islets containing cells.

[0183] 55. Use of ISX9 and Wnt-C59 in inducing differentiation of pancreatic progenitor cells into pancreatic endocrine precursor cells.

[0184] Working Example The following examples are set forth to illustrate and aid in the understanding of the present invention and should not be construed in any way as limiting the scope of the invention as defined in the claims which follow thereafter.

[0185] method Cell sources and culture Home-grown human pluripotent stem cells (hPSCs) by chemical reprogramming of fibroblasts were cultured in mTeSR1 (Stem Cell, Cat. No. 85850) on Matrigel-coated (BD BioSciences, Cat. No. 356231) plates or dishes diluted 1:40. Medium was changed daily. Cultures were passaged by ReleSR (Stem Cell, Cat. No. 05872) at a split ratio of 1:10 to 1:15 every 5–6 days.

[0186] In vitro differentiation to generate hPSC-islets Prior to differentiation, adherent hPSCs were dispersed into single cells using Accutase (EMD Millipore, Cat. No. SCR005), rinsed with DMEM / F12 (Gibco, Cat. No. 11330-032), and seeded onto Matrigel-coated plates or dishes in mTESR1 supplemented with 10 mM Y27632. Differentiation was initiated 24 hours after seeding.

[0187] Detailed information of the small molecules and cytokines used in the differentiation process is listed in Table 1. [Table 1]

[0188] The media formulations for each stage are as follows (proportions are calculated by volume unless otherwise indicated):

[0189] Stage 1 (4 days): MCDB131 (Gibco, Cat. No. 10372-019) was supplied with 4.5 mM glucose (Sigma, Cat. No. G7021), 1% Glutamax (Gibco, Cat. No. 35050-061), 1% Pen / Strep, 1% B27 (Gibco, Cat. No. 12587-010), 100 ng / mL activin A, 0.25 mM vitamin C, 6 μM Chir99021, 50 nM PI103 and 10 μM Y27632 only on day 1. For days 2-4, the culture medium was refreshed daily in MCDB131 containing 4.5 mM glucose, 1% Glutamax, 1% Pen / Strep, 1% B27, 50 ng / mL activin A and 0.25 mM vitamin C.

[0190] Stage 2 (2 days): MCDB131 supplemented with 4.5 mM glucose, 1% Glutamax, 1% Pen / Strep, 0.5% BSA (Sigma, Cat. No. A4612) or 1% B27, 50 ng / mL KGF, 0.25 mM Vitamin C, 5 μM SB431542 and 100 nM Wnt-C59.

[0191] Stage 3 (4 days): DMEM-basic (Gibco, Cat. No. C11965500BT) supplemented with 1% Pen / Strep, 1% B27, 2 μM retinoic acid, 0.1 μM LDN193189, 0.25 μM Sant1 and 100 nM Wnt-C59. At the end of stage 3, cells were dispersed by exposure to Accutase. Released cells were rinsed with DMEM-basic and spun down at 300 g for 3 min. Cells were then seeded in 6-well AggreWell™ microwell plates (Stem Cell, Cat. No. 27940) in stage 4 medium supplemented with 10 μM Y27632 and spun down to the bottom of the microwells by centrifuging the plate at 300 g for 5 min. The cells were then incubated at 37°C with 5% CO2 for 20 hours and the resulting cell clusters were transferred to ultra-low attachment 6-well plates (Beaverbio, Cat. No. 40406) containing stage 4 medium. The suspended aggregates were cultured in an incubator shaker (Infors-HT, Multitron) at a rotation speed of 90 rpm at 37°C, 5% CO2 and 85% humidity.

[0192] Stage 4 (5-6 days). DMEM basic supplemented with 1% Pen / Strep, 1% Glutamax, 1% B27, 100 ng / mL EGF, 0.2 μM TPB, 10 mM nicotinamide, 0.25 μM Sant1 and 0.25 mM vitamin C.

[0193] Stage 5 (6 days). DMEM basic supplemented with 1% Pen / Strep, 1% Glutamax, 1% B27, 10 μM ALK5 inhibitor II, 0.3 μM LDN193189, 1 μM T3, 10 μM ISX9, 10 μg / mL heparin, 0.1 μM γ-secretase inhibitor Xxi, 100 nM Wnt-C59, 10 μM Y27632 and 0.25 mM Vitamin C.

[0194] Stage 6 (2–4 days). DMEM-basic supplemented with 1% Pen / Strep, 1% B27, 10 μM ALK5 inhibitor II, 0.5 μM R428, 1 μM T3, 10 μM forskolin, 10 μg / mL heparin, 10 μM zinc sulfate, 2 mM N-acetylcysteine, and 0.25 mM vitamin C.

[0195] Flow cytometry Differentiated cells were released into a single cell suspension using Accutase and then stained for surface and intracellular markers. The antibodies used are listed in Table 2. [Table 2]

[0196] Immunohistochemistry and immunofluorescence staining Frozen tissue sections. Cell aggregates or tissues were washed with PBS and fixed in 4% PFA (Biosharp, Cat. No. BL539A) for 2 hours (cell aggregates) or 24 hours (tissues) at 4°C. Samples were washed three times with PBS and dehydrated overnight at 4°C in 30% sucrose solution. Samples were overlaid with OCT (Sakura, Cat. No. 4583) solution, frozen using liquid nitrogen, and stored at -80°C. 10 μm sections were cut using a freezing microtome and placed on slides. Slides were washed with PBS and permeabilized with PBST solution (PBS + 0.2% Triton X-100 + 5% donkey serum) for 1 hour at room temperature. Slides were incubated overnight at 4°C with primary antibodies diluted in PBST solution. After washing three times with PBS, slides were incubated with secondary antibodies conjugated to Alexa Fluor® 488, 555 or 647 (Life Technologies) at 1:1000 in PBST solution for 1 h and stained with DAPI for 5 min at room temperature. Images were captured using a Leica TCS SP8 confocal microscope.

[0197] All antibodies used above are listed in Table 3. [Table 3]

[0198] qRT-PCR Total RNA was extracted using RNeasy Mini Kit (QIAGEN, Cat. No. 74004) according to the manufacturer's instructions. cDNA was synthesized using Transcript One-Step GDNA Removal and cDNA Synthesis Supermix (TransGen Biotech, Cat. No. AT311-03). KAPA SYBR® FAST Universal qPCR Mix (KAPA Biosystems, Cat. No. KK4601) was used for qRT-PCR analysis, which was performed on a BIO-RAD CFX384™ Real-Time System. All relative expression levels were normalized to the housekeeping gene GAPDH, and the results were analyzed using the ΔΔCt method. Primers are listed in Table 4. [Table 4]

[0199] Glucose-stimulated insulin secretion (GSIS) Krebs buffer was prepared as follows: 129 mM NaCl, 4.8 mM KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, 1 mM Na2HPO4, 1.2 mM KH2PO4, 5 mM NaHCO3, 10 mM HEPES, 0.2% BSA in deionized and sterile filtered water. Krebs buffer containing 2.8 mM glucose, 16.7 mM glucose and 30 mM KCl was prepared and warmed to 37°C.

[0200] Static GSIS. hPSC-islets (20-50 clusters) or human islets (20-50 islets) were collected and placed in 24-well plates, then rinsed twice with Krebs buffer. Cells were successively incubated for 1 h at 37°C in Krebs buffer, Krebs buffer containing 2.8 mM glucose, Krebs buffer containing 16.7 mM glucose, and Krebs buffer containing 30 mM KCl. Supernatants were collected after each incubation, and cells were rinsed with fresh Krebs buffer at each solution change. Supernatant samples were frozen at -80°C until detection was performed. After the assay, cells were dispersed into single cells using Accutase and counted using a Countess™ II Automated Cell Counter.

[0201] Dynamic GSIS. The dynamic function of hPSC-islets was assessed using an automated perfusion system (Biorep® Perifusion System; BioRep). hPSC-islets were exposed to glucose Krebs buffer and KCl Krebs buffer and assayed with the effluent collected at a flow rate of 100 μL / min. 2.8 mM glucose Krebs buffer was perfused for the first 60 min to allow equilibration. The solutions were then switched as follows: 2.8 mM glucose Krebs buffer for 15 min, 16.7 mM glucose Krebs buffer for 30 min, 2.8 mM glucose Krebs buffer for 15 min, and 30 mM KCl Krebs buffer for 15 min.

[0202] ELISA C-peptide, insulin and glucagon levels were detected using human C-peptide ELISA kit (ALPCO, Cat. No. 80-CPTHU-E10), human insulin ELISA kit (ALPCO, Cat. No. 80-INSHUU-E10) and human glucagon ELISA kit (Mercodia, Cat. No. 10-1271-01) according to the manufacturer's instructions.

[0203] Electron microscopy hPSC-islets were processed by the Center of Cryo-Electron (CCEM) of Zhejiang University. Grids were examined with a Tecnai G2 Spirit electron microscope.

[0204] Transplantation into mice All mouse experimental procedures were performed in accordance with the animal protection guidelines of Peking University (China). Male CB17.Cg-PrkdcscidLystbg-J / Crl (Scid / Beige) mice aged 6–8 weeks were purchased from Beijing Vital River Laboratory Animal Technology Co, Ltd.

[0205] Transplantation into STZ-treated diabetic mice. Diabetes was induced by intraperitoneal injection of 70 mg / kg STZ (Selleck, Cat. No. S1312) after 16 h fasting for 5 consecutive days. Approximately 3 × 10 6 hPSC-islet cells were transplanted. Fasting blood glucose levels after 16 h fasting were monitored weekly with a handheld glucometer (ROCHE, Cat. No. 06870279001) using tail bleeding. Animals were weighed weekly. Glucose-stimulated human C-peptide secretion was assessed by taking blood samples after 16 h fasting and 30 min after glucose injection (2 g / kg, 30% solution, ip). For glucose tolerance test, intraperitoneal injection of glucose (2 g / kg, 30% solution) was performed after 16 h fasting and blood glucose levels were monitored at predefined time points (0 min, 5 min, 15 min, 30 min, 60 min, 90 min and 120 min). Plasma was frozen at -80 °C until human C-peptide analysis.

[0206] Transplantation into non-STZ-treated healthy mice. Approximately 3 × 10 6 hPSC-islet cells were transplanted. Blood samples after 16 h fasting were collected every two weeks for fasting human C-peptide measurements. Plasma was frozen at -80°C until human C-peptide analysis.

[0207] Transplantation in non-human primates All monkey experimental procedures were approved by the Institutional Animal Care and Use Committee of Institute of Medical Biology, Chinese Academy of Medical Science (Ethics Number: DWLL201908013). Four male rhesus macaques (4 years old, 4–5.5 kg) from the Institute of Medical Biology Chinese Academy of Medical Science were used as recipients of hCiPC-islet transplantation.

[0208] Diabetes induction. Diabetes was induced according to previously reported methods. Briefly, after an overnight fast, a single dose of STZ (90 mg / kg, Adooq, Cat. No. A10868) was injected intravenously (within 5 min). STZ was diluted in 0.1 M citrate buffer (pH 4.3-4.5) and immediately administered intravenously rapidly, followed by normal saline (40-50 mL) for hydration. Omeprazole (0.5 mg / kg, Losec®, Astrazeneca AB) was injected to prevent nausea and vomiting after hydration. Blood glucose was monitored hourly for the first 12 h after STZ injection and then four times a day. Exogenous insulin injections were started 3 days after STZ treatment. Short-acting insulin (Humalog®, Eli Lilly Italia SpA) and long-acting insulin (Lantus®, Sanofi-Aventis Deutschland GmbH) were injected subcutaneously. Blood glucose, C-peptide and HbA1c levels were recorded before hPSC-islet transplantation.

[0209] Transplantation surgery. The transplantation procedure was performed after confirming the diabetic status of the recipient monkey. After iv administration of propofol (0.5 mL / kg, Petsun Therapeutics), the monkey was anesthetized with inhalable isoflurane. Heart rate, body temperature, blood oxygenation, and blood pressure were monitored in real time during the surgical procedure. 5% glucose was infused to maintain blood glucose levels. After laparotomy, a total of approximately 4–6 × 10 8 hPSC-islet cells were injected into the portal vein via the jejunal vein.

[0210] To mitigate this thrombosis, low molecular weight sodium heparin (150 IU / kg, ihFluxum®, Alfasigma SpA) was injected subcutaneously 2 and 8 hours after surgery, followed by injections three times a day for approximately one week. Antibiotic treatment was continued for 7 days. Pain relief medication was administered for the first 3 days after cell injection.

[0211] Routine laboratory tests. C-peptide secretion, body weight, HbA1c, complete blood count, serum creatinine and liver function analyses were performed routinely. Complete blood counts were performed using a Sysmex XT-200i. HbA1c, serum creatinine and liver function analyses were evaluated using a Mindray BS-2000.

[0212] statistical analysis Data analysis was performed using GraphPad Prism software. Statistical significance was assessed by t-test. Throughout, n represents the number of biological replicates unless otherwise stated. P values ​​are indicated as follows: *P<0.05; **P<0.005; ***P<0.0005; ****P<0.00005.

[0213] Example 1. Characterization of hPSC-islets The hPSC-derived pancreatic islets (hPSC-islets) obtained by the methods described above were characterized in vitro.

[0214] Immunostaining showed that most C-peptide-positive cells co-expressed transcription factors for pancreatic endocrine cells and mature β cells (Figure 5d). The levels of secreted C-peptide were comparable in hPSC-islets and primary human islets (Figure 5e). Importantly, the ability to respond to a glucose load with dynamic biphasic insulin secretion and the presence of dense-core crystallized insulin granules suggested mature insulin secretion function of hPSC-islets (Figures 5f and g).

[0215] In addition to β cells, glucagon (GCG)-positive α cells and somatostatin (SST)-positive δ cells were also identified in the aggregates (Fig. 1c). GCG secretion was detectable and suppressed upon glucose loading (Fig. 5h). Flow cytometry analysis revealed that hPSC-islets contained, on average, approximately 60% β cells, 11% α cells, and 7% δ cells (Fig. 1d).

[0216] Furthermore, the functionality of hPSC-islets was validated in a routinely used immunodeficient mouse model. After transplantation under the kidney capsule of streptozotocin (STZ)-induced diabetic mice, hPSC-islets upregulated C-peptide uptake 16 weeks after transplantation (wpt). + β cells, GCG + Alpha cells and SST + The hPSC-islet-transplanted mice survived with prominent vascularization and preserved cellular complexity, as indicated by the presence of δ-cells (Figure 1e and Figure 5i). The fasting blood glucose levels of the transplanted mice were restored to physiological levels accompanied by an increase in body weight (Figure 1f and Figure 5j). A glucose tolerance test showed glucose-responsive human C-peptide secretion as well as rapid glucose clearance (Figure 1g and Figure 5k). Fasting human C-peptide secretion steadily increased from 2 to 12 wpt and was then maintained at approximately 1 ng / mL for up to 36 weeks in nondiabetic mice (Figure 1h). Notably, the 15-week survival rate of hPSC-islet-transplanted diabetic mice was over 85%, compared with less than 20% in the nontransplanted control group (Figure 5I). These results indicated that hPSC-islets could reverse diabetes in a mouse model.

[0217] Example 2. Compatibility between cell lines Furthermore, the established protocol showed good compatibility across cell lines, as indicated by the recapitulation of similar in vitro characteristics and in vivo functionality in hPSC-islets derived from three separate independent hPSC cell lines (Figure 6 and Table 5). Notably, no tumor formation was observed in any mice transplanted with hPSC-islets (n=190). [Table 5]

[0218] Example 3. Efficacy and safety of hPSC-islet transplantation in a non-human primate model Next, we investigated the efficacy and safety of hPSC-islet transplantation in a non-human primate model that more closely mimics humans compared with mouse models.

[0219] Four healthy adult rhesus macaques (Macaca mulatta) were used in this study (Table 6). All four macaques developed diabetes after a single high-dose STZ injection, resulting in fasting blood glucose levels above 200 mg / dL and C-peptide levels below 0.15 ng / mL (0.09 ± 0.03 ng / mL) (Figures 2a-d and 4a-d). Exogenous insulin was administered 3 days after STZ injection. The exogenous insulin requirements of the four diabetic recipients ranged from 2 to 4 IU / kg / day (2.89 ± 0.58 IU / kg / day) 1 week before cell transplantation, comparable to previous reports (Figures 3a-d). Although all macaques were treated with intensive insulin therapy, their levels of glycated hemoglobin A1c (HbA1c) dramatically increased from 3.9 ± 0.5% to 7.2 ± 1.4% within 1-2 months after STZ injection, indicating rapid progression of diabetes (Figure 2i-l). Notably, we observed that monkey-#3 exhibited features of unstable diabetes, indicated by fluctuating blood glucose levels ranging from 40 to 545 mg / dL within a day and fasting blood glucose levels ranging from 40 to 450 mg / dL before cell transplantation (Figure 2c).

[0220] To generate a ready-to-use cell source for macaque transplantation, we optimized cryopreservation and recovery protocols for hPSC-islets. After generation, hPSC-islets were cryopreserved as single cells, then harvested and reaggregated 2 days before infusion. The average viability and yield of hPSC-islets after harvesting were 86.9%±1.6% and 82.0%±9.5%, respectively (Table 6). [Table 6-1] [Table 6-2]

[0221] The harvested hPSC-islets were transplanted into diabetic macaques in a single dose by intraportal vein infusion. After hPSC-islet transplantation, all four recipients showed mitigation of diabetic symptoms (Figs. 2 and 3). First, fasting blood glucose levels were reduced and stabilized over time (Fig. 2a–d), and a clear downward trend was observed at 1 month post-transplantation, especially in monkey-#4 (Fig. 2d). Second, the mean pre-prandial blood glucose levels were also significantly reduced in all recipients after hPSC-islet infusion (Fig. 2e–h). Accordingly, HbA1c, a universal clinical measure for glycemic control in diabetic patients, was reduced on average from 7.2 ± 1.4% before transplantation to 5.0 ± 0.2% by the day of submission (Fig. 2i–l). Notably, these improvements were also seen in monkey-#3, a recipient that showed an unstable diabetic-like state after STZ injection (Fig. 2c, g and k). Taken together, these results revealed that hPSC-islet transplantation effectively reduced hyperglycemia and improved overall glycemic control in all diabetic macaques.

[0222] Moreover, exogenous insulin requirements were dramatically reduced after hPSC-islet transplantation (Figure 3a-d). A decrease in exogenous insulin requirements was noted in all recipients 1-2 weeks after hPSC-islet infusion, which could be attributed to reduced appetite during the post-surgery recovery period and strong immunosuppression around the time of transplantation. Exogenous insulin requirements increased upon return to a normal diet. As hPSC-islets engrafted and matured in vivo, exogenous insulin requirements gradually decreased and stabilized over time. Fifteen weeks after hCiPSC-islet infusion, exogenous insulin requirements in the four recipients were reduced by 31% (from 2.12 to 1.46 IU / kg / day), 60% (from 3.52 to 1.41 IU / kg / day), 54% (from 3.09 to 1.41 IU / kg / day), and 52% (from 2.89 to 1.40 IU / kg / day) compared to pre-transplant levels (Figure 3a-d). Meanwhile, the body weight of recipient macaques increased 6 weeks after hPSC-islet infusion (Figure 3e-h).

[0223] C-peptide secretion was monitored continuously in all macaques. A progressive increase in secreted C-peptide levels was observed in all recipients within the first 1–2 months after hPSC-islet infusion, suggesting functional maturation of hPSC-islets in vivo (Figure 4a–d). Furthermore, C-peptide secretion responded to a meal challenge starting from 4–8 wpt in all recipients (Figure 4e–h). In monkey-#2, the fold change in postprandial C-peptide levels from fasting levels exceeded 3 from 8–16 wpt (Figure 4f). The level of C-peptide secretion peaked within 8 wpt, with the mean secretion level being 0.37 ± 0.29 ng / mL at 8 wpt, a notable increase from pretransplant levels (0.09 ± 0.03 ng / mL) (Figure 4e–h). The significant increase in secreted C-peptide levels in all recipients was consistent with the observed improvement in glycemic control and reduced exogenous insulin requirements.

[0224] In summary, we demonstrate that islets derived from human pluripotent stem cells can survive for long periods in preclinical settings, attenuate hyperglycemia, and improve overall glycemic control. First, hPSC-islet transplantation effectively reduces HbA1c and restores endogenous C-peptide secretion (Figs. 2-4), positive results indicating control of disease progression. Clinical studies associate every percentage point reduction in HbA1c with a significant reduction in the risk of diabetes-related complications. Moreover, restoration of endogenous C-peptide has also been recognized as a major factor associated with overall clinical benefit in clinical islet transplantation. Second, we observed that one recipient macaque exhibiting features of unstable diabetes benefited from hPSC-islet transplantation (Fig. 2c, g, and k). Clinical reports provided strong evidence that refractory hypoglycemia, a primarily life-threatening symptom in patients with "brittle diabetes," can be resolved with clinical islet cell transplantation. Although more animals should be tested, our data suggest the potential of hPSC-islet infusion in improving glycemic control and correcting severe hypoglycemia in this select group of unstable diabetic patients. Finally, the ability to be efficiently cryopreserved makes hPSC-islets a consistently available, ready-to-use cell source, which is particularly important for clinical applications and gives much-needed flexibility in transplantation into humans. Taken together, as the first comprehensive report on the long-term evaluation of hPSC-islets in a primate model of diabetes, the data obtained in this study could provide useful insights into stem cell-derived islets in clinical research for diabetes treatment.

[0225] The present disclosure has been described above with reference to its embodiments. It should be understood that various modifications, changes and additions can be made by those skilled in the art without departing from the spirit and scope of the present disclosure. Therefore, the scope of the present disclosure is not limited to the above specific embodiments, but is defined only by the appended claims.

Claims

1. C-peptide + Cells, Glucagon + Cells and Somatostatin + 1. A method for generating functional human PSC-islet containing cells in vitro, comprising: (1) culturing the hPSCs in a sixth culture medium to obtain cells expressing markers characteristic of definitive endoderm; (2) culturing the cells obtained in step (1) in a fifth culture medium to obtain cells expressing markers characteristic of primitive intestinal cells; (3) culturing the cells obtained in step (2) in a fourth culture medium to obtain cells expressing markers characteristic of posterior foregut cells; (4) culturing the cells obtained in step (3) in a third culture medium to obtain cells expressing markers characteristic of pancreatic progenitor cells; (5) culturing the cells obtained in step (4) in a second culture medium to obtain cells expressing markers characteristic of pancreatic endocrine precursor cells; (6) culturing the cells obtained in step (5) in a first culture medium to obtain cells expressing markers characteristic of functional hPSC-islets; The method, wherein said second culture medium is supplemented with ISX9 and / or Wnt-C59.

2. The method of claim 1, wherein the second culture medium is supplemented with ISX9 and Wnt-C59.

3. the first culture medium comprising an ALK5 inhibitor, an adenylyl cyclase activator, an Axl inhibitor, an IκB kinase inhibitor, T3 and ZnSO 4 3. The method of claim 1 or claim 2, comprising a basal medium supplemented with one or more of:

4. The method of any one of claims 1 to 3, wherein the second culture medium comprises a basal medium further supplemented with one or more of an inhibitor of ALK5, an inhibitor of BMP signaling, a thyroid hormone and an inhibitor of NOTCH signaling.

5. 5. The method of any one of claims 1 to 4, wherein the third culture medium comprises a basal medium supplemented with one or more of epidermal growth factor, an activator of protein kinase C, an inhibitor of sonic hedgehog signaling and a vitamin B complex component.

6. 6. The method of any one of claims 1 to 5, wherein the fourth culture medium is supplemented with one or more of retinoic acid (RA), an inhibitor of sonic hedgehog signaling, and an inhibitor of BMP signaling.

7. The method of claim 6 , wherein the fourth culture medium is further supplemented with an inhibitor of Wnt signaling.

8. The method of claim 7, wherein the inhibitor of Wnt signaling is Wnt-C59.

9. The method of any one of claims 1 to 8, wherein the fifth culture medium comprises a basal medium supplemented with an activator of FGF signaling.

10. 10. The method of claim 9, wherein the fifth culture medium is further supplemented with a TGF-β / Smad inhibitor and / or a Wnt inhibitor.

11. The method of claim 10, wherein the Wnt inhibitor is Wnt-C59.

12. 12. The method of any one of claims 1 to 11, wherein the sixth culture medium comprises a basal medium supplemented with one or more of an activator of an activin receptor, a Wnt activator, a ROCK inhibitor, and a PI3K inhibitor.

13. The method of any one of claims 1 to 12, wherein the hPSCs are embryonic stem cells or induced pluripotent stem cells.

14. The method according to any one of claims 1 to 13, wherein one or more of the cultures in steps (1) to (6) are suspension cultures.

15. The method according to claim 14, wherein the culture in steps (1) to (3) is a suspension culture.

16. The method of any one of claims 1 to 15, wherein step (1) further comprises culturing in a seventh culture medium after culturing in the sixth culture medium and before step (2), and the seventh culture medium comprises a basal medium supplemented with glucose, L-glutamine, B27, activin A and vitamin C.

17. A population of cells comprising functional hPSC-islets obtainable by the method according to any one of claims 1 to 16.

18. A pharmaceutical composition comprising the population of cells described in claim 17.

19. 19. The population of cells of claim 17 or the pharmaceutical composition of claim 18 for treating a mammal having or at risk of having type I diabetes, type II diabetes, prediabetes, or any combination thereof.

20. C-peptide + Cells, Glucagon + Cells and Somatostatin + 1. A kit for generating functional human PSC-islets containing cells, comprising: A kit comprising at least one selected from the group consisting of the first to sixth culture media defined in any one of claims 1 to 15, and the seventh culture medium defined in claim 16.

21. Use of ISX9 and Wnt-C59 in inducing differentiation of pancreatic progenitor cells into pancreatic endocrine precursor cells.